Tag Archives: genomics

GenProbe (GPRO) Sells Off After ThermoFisher (TMO) Announces Phadia Buyout

But ThermoFisher (TMO $65.12) is Up 3.78% on Volume of 3.2M Shares GenProbe (GPRO $84.10) down 2.9% sold off some of of the speculative gains from yesterday after ThermoFisherScientific (TMO) announced it was buying Phadia, a privately held Swedish diagnostic Company for $3.5B in cash. Phadia was sold by Pfizer in 2004 to private equity [...]

Comments Off Continue Reading →

Big Sell-Off in Oil, Gas and Other Commodities Spooks the Market

Relative Safety in Healthcare Stocks Today’s sell-off in the energy complex with the back-drop of a U.S. slow growth scenario plus the Euro being vulnerable due to Greece and Ireland has spooked the overall market. All the major indices are down over 1% with the S&P down 1.22%. Nasdaq is coming back down only 1%.Materials [...]

Comments Off Continue Reading →

Life Science Stocks Capture M&A Premium

Deals Are Bullish for the Market Yesterday’s Alkermes (ALKS) deal with Elan (ELN) supports the major M&A trend in the life science market. Timing is everything in a hot market. The rationale for the current M&A activity is:  technologies and pipeline fit strategically, money is cheap, and growth (growing internally takes too long). The parade [...]

Comments Off Continue Reading →

Ariad (ARIA) and MolecularMD Collaborate in Companion Dx for CML

Ariad (ARIA $7.24 up 4.3%) continues to roll on today on heavy volume up 17% over 5 days on speculation, news and upgrades with strong expectations for their chronic myeloid leukemia drug ponatinib. Articles from Motley Fool, Seeking Alpha and The Street.com have spotlighted the  Company and potential news at the ASCO Meeting which is [...]

Comments Off Continue Reading →

Healthcare Start-Ups: What’s Hot?

Hot biomedical concepts: Software, mobile communications, ophthalmology,antibiotics,epilepsy,surgery,cancer, and publishing. On Thursday March 9 The Wall Street Journal published an excellent review of the Top 50 start-ups and the money raised.The leaders were technology companies with a WEB focus. With valuations for Facebook, Group-On and Twitter soaring there is some debate as to whether we are [...]

Comments Off Continue Reading →

Rayno Life Science Portfolio Update: BLUD,ILMN, NEOG,SQNM

Immucor (BLUD) stock was up 5.7% to $18.91 on news that the DOJ closed its anti-trust investigation. The stock hit a low in early October when it slashed guidance due to lower utility of blood transfusion services.The Company is  a leader in automated blood transfusion systems but still faces litigation regarding price fixing and regulatory [...]

Comments Off Continue Reading →